Effect on renal function of an iso-osmolar contrast agent in patients with monoclonal gammopathies

Lorenzo Preda, Alberto Agazzi, Sara Raimondi, Carla Federica Lanfranchi, Rita Passerini, Albania Calvetta, Giovanni Martinelli, Massimo Bellomi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To assess the safety of the non-ionic iso-osmolar contrast agent iodixanol on renal function in patients with monoclonal gammopathies undergoing CT. Methods: We explored the effect of iodixanol on renal function in 30 patients with monoclonal gammopathies and 20 oncological patients with a normal electrophoretic profile (control group). The parameters used to estimate renal function were: serum creatinine, eGFR (determined 24 h before and 48 h after the administration of iodixanol), and urinary excretion of Neutrophil Gelatinase-Associated Lipocalin (NGAL) determined 2 h and 24 h after. Serum creatinine was also determined 1 month after the administration of iodixanol. Results: No significant increase in serum creatinine values were observed in the monoclonal gammopathies group and in 19/20 patients in the control group. Only 1 patient in the control group developed a transient contrast agent-induced nephropathy. We found no statistically significant difference between the two groups regarding the percentage variation from baseline values of serum creatinine, creatinine clearance, NGAL 2 h after, and eGFR. Whereas NGAL at 24 h showed a statistically significant increase in patients with Monoclonal gammopathies. Conclusion: The use of iodixanol appears to be safe in patients with monoclonal gammopathies and an eGFR ≥∈60 ml/min/1.73 mq.

Original languageEnglish
Pages (from-to)63-69
Number of pages7
JournalEuropean Radiology
Volume21
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Paraproteinemias
Contrast Media
Kidney
Creatinine
Serum
Control Groups
iodixanol
Lipocalin-2
Safety

Keywords

  • Computed tomography
  • Contrast-induced nephropathy
  • Iodinated contrast medium
  • Monoclonal gammopathy
  • Multiple myeloma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Effect on renal function of an iso-osmolar contrast agent in patients with monoclonal gammopathies. / Preda, Lorenzo; Agazzi, Alberto; Raimondi, Sara; Lanfranchi, Carla Federica; Passerini, Rita; Calvetta, Albania; Martinelli, Giovanni; Bellomi, Massimo.

In: European Radiology, Vol. 21, No. 1, 01.2011, p. 63-69.

Research output: Contribution to journalArticle

Preda, Lorenzo ; Agazzi, Alberto ; Raimondi, Sara ; Lanfranchi, Carla Federica ; Passerini, Rita ; Calvetta, Albania ; Martinelli, Giovanni ; Bellomi, Massimo. / Effect on renal function of an iso-osmolar contrast agent in patients with monoclonal gammopathies. In: European Radiology. 2011 ; Vol. 21, No. 1. pp. 63-69.
@article{8ca14f6da98443519bb119ab637e2e73,
title = "Effect on renal function of an iso-osmolar contrast agent in patients with monoclonal gammopathies",
abstract = "Objective: To assess the safety of the non-ionic iso-osmolar contrast agent iodixanol on renal function in patients with monoclonal gammopathies undergoing CT. Methods: We explored the effect of iodixanol on renal function in 30 patients with monoclonal gammopathies and 20 oncological patients with a normal electrophoretic profile (control group). The parameters used to estimate renal function were: serum creatinine, eGFR (determined 24 h before and 48 h after the administration of iodixanol), and urinary excretion of Neutrophil Gelatinase-Associated Lipocalin (NGAL) determined 2 h and 24 h after. Serum creatinine was also determined 1 month after the administration of iodixanol. Results: No significant increase in serum creatinine values were observed in the monoclonal gammopathies group and in 19/20 patients in the control group. Only 1 patient in the control group developed a transient contrast agent-induced nephropathy. We found no statistically significant difference between the two groups regarding the percentage variation from baseline values of serum creatinine, creatinine clearance, NGAL 2 h after, and eGFR. Whereas NGAL at 24 h showed a statistically significant increase in patients with Monoclonal gammopathies. Conclusion: The use of iodixanol appears to be safe in patients with monoclonal gammopathies and an eGFR ≥∈60 ml/min/1.73 mq.",
keywords = "Computed tomography, Contrast-induced nephropathy, Iodinated contrast medium, Monoclonal gammopathy, Multiple myeloma",
author = "Lorenzo Preda and Alberto Agazzi and Sara Raimondi and Lanfranchi, {Carla Federica} and Rita Passerini and Albania Calvetta and Giovanni Martinelli and Massimo Bellomi",
year = "2011",
month = "1",
doi = "10.1007/s00330-010-1908-2",
language = "English",
volume = "21",
pages = "63--69",
journal = "European Radiology",
issn = "0938-7994",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Effect on renal function of an iso-osmolar contrast agent in patients with monoclonal gammopathies

AU - Preda, Lorenzo

AU - Agazzi, Alberto

AU - Raimondi, Sara

AU - Lanfranchi, Carla Federica

AU - Passerini, Rita

AU - Calvetta, Albania

AU - Martinelli, Giovanni

AU - Bellomi, Massimo

PY - 2011/1

Y1 - 2011/1

N2 - Objective: To assess the safety of the non-ionic iso-osmolar contrast agent iodixanol on renal function in patients with monoclonal gammopathies undergoing CT. Methods: We explored the effect of iodixanol on renal function in 30 patients with monoclonal gammopathies and 20 oncological patients with a normal electrophoretic profile (control group). The parameters used to estimate renal function were: serum creatinine, eGFR (determined 24 h before and 48 h after the administration of iodixanol), and urinary excretion of Neutrophil Gelatinase-Associated Lipocalin (NGAL) determined 2 h and 24 h after. Serum creatinine was also determined 1 month after the administration of iodixanol. Results: No significant increase in serum creatinine values were observed in the monoclonal gammopathies group and in 19/20 patients in the control group. Only 1 patient in the control group developed a transient contrast agent-induced nephropathy. We found no statistically significant difference between the two groups regarding the percentage variation from baseline values of serum creatinine, creatinine clearance, NGAL 2 h after, and eGFR. Whereas NGAL at 24 h showed a statistically significant increase in patients with Monoclonal gammopathies. Conclusion: The use of iodixanol appears to be safe in patients with monoclonal gammopathies and an eGFR ≥∈60 ml/min/1.73 mq.

AB - Objective: To assess the safety of the non-ionic iso-osmolar contrast agent iodixanol on renal function in patients with monoclonal gammopathies undergoing CT. Methods: We explored the effect of iodixanol on renal function in 30 patients with monoclonal gammopathies and 20 oncological patients with a normal electrophoretic profile (control group). The parameters used to estimate renal function were: serum creatinine, eGFR (determined 24 h before and 48 h after the administration of iodixanol), and urinary excretion of Neutrophil Gelatinase-Associated Lipocalin (NGAL) determined 2 h and 24 h after. Serum creatinine was also determined 1 month after the administration of iodixanol. Results: No significant increase in serum creatinine values were observed in the monoclonal gammopathies group and in 19/20 patients in the control group. Only 1 patient in the control group developed a transient contrast agent-induced nephropathy. We found no statistically significant difference between the two groups regarding the percentage variation from baseline values of serum creatinine, creatinine clearance, NGAL 2 h after, and eGFR. Whereas NGAL at 24 h showed a statistically significant increase in patients with Monoclonal gammopathies. Conclusion: The use of iodixanol appears to be safe in patients with monoclonal gammopathies and an eGFR ≥∈60 ml/min/1.73 mq.

KW - Computed tomography

KW - Contrast-induced nephropathy

KW - Iodinated contrast medium

KW - Monoclonal gammopathy

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=78650550198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650550198&partnerID=8YFLogxK

U2 - 10.1007/s00330-010-1908-2

DO - 10.1007/s00330-010-1908-2

M3 - Article

C2 - 20680288

AN - SCOPUS:78650550198

VL - 21

SP - 63

EP - 69

JO - European Radiology

JF - European Radiology

SN - 0938-7994

IS - 1

ER -